1. Home
  2. IRIX vs QNCX Comparison

IRIX vs QNCX Comparison

Compare IRIX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IRIDEX Corporation

IRIX

IRIDEX Corporation

HOLD

Current Price

$0.70

Market Cap

15.0M

Sector

Health Care

ML Signal

HOLD

Logo Quince Therapeutics Inc.

QNCX

Quince Therapeutics Inc.

HOLD

Current Price

$31.32

Market Cap

17.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRIX
QNCX
Founded
1989
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.0M
17.5M
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
IRIX
QNCX
Price
$0.70
$31.32
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
86.0K
19.2K
Earning Date
05-12-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
51.85
N/A
EPS
N/A
N/A
Revenue
$41,593,000.00
N/A
Revenue This Year
$3.07
N/A
Revenue Next Year
$6.66
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.70
$0.08
52 Week High
$1.65
$35.41

Technical Indicators

Market Signals
Indicator
IRIX
QNCX
Relative Strength Index (RSI) 31.53 59.68
Support Level $0.70 $29.95
Resistance Level $1.14 $35.41
Average True Range (ATR) 0.04 2.22
MACD 0.00 -0.79
Stochastic Oscillator 0.54 37.09

Price Performance

Historical Comparison
IRIX
QNCX

About IRIX IRIDEX Corporation

IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.

Share on Social Networks: